Post Market In-vitro Bioequivalence Study on Representative Brands of Ciprofloxacin Tablets (500 mg) Prescribed in Typhoid Disease

Muhammad Azeem^{1, 2,} , Humaira Naureen¹ and Madeeha Malik²

¹Department of Pharmaceutics, Riphah Institute of Pharmaceutical Sciences, Islamabad, Pakistan

²Department of Pharmacy, Hamdard Institute of Pharmaceutical Sciences, Islamabad, Pakistan

Cite this paper:
Muhammad Azeem, Humaira Naureen and Madeeha Malik. Post Market In-vitro Bioequivalence Study on Representative Brands of Ciprofloxacin Tablets (500 mg) Prescribed in Typhoid Disease. American Journal of Pharmacological Sciences. 2014; 2(5B):8-11. doi: 10.12691/ajps-2-5B-3

Abstract

Seven brands of ciprofloxacin (One multinational and six local) were evaluated in terms of their bioavailability and efficacy. Pharmaceutical Parameters like weight variation, hardness, disintegration, dissolution and content assay were determined. Antibacterial susceptibility assay was performed on standard Strain of Salmonella typhi (ATCC 14028). MIC and ZOI were assessed. The results of the study indicated that three local brands had content less than the stated claim of USP and one brand did not pass the disintegration and dissolution tests, so they cannot be used as therapeutic alternatives. Antibacterial assay showed less MIC value of the brands having greater drug content while drug with lesser amount had greater MIC value. Similarly, one local brand showed greater zone of inhibition (ZOI) as compared to multinational brand having more price than the local brand.

Keywords:
minimum Inhibitory concentration (MIC) zone of inhibition (ZOI) United States Pharmacopoeia (USP) World Health Organization (WHO) Gastro-Intestinal Track (GIT) Muller Hinton Agar (MHA) Irrational Drug Use (IRDU)

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	N. C. Ngwuluka, k. lawal, P. O. olorunfemiand N. A. Ochekpe. Post-market in vitro bioequivalence study of six brands of ciprofloxacin tablets/caplets in jos, Nigeria, Scientific research and essay, Vol. 4 (4), pp. 298-305, April, 2009.
[2]	Raheela. B, Shahnaz. G, Syed Baqir. S.N and Shoukat.M. Pharmaceutical evaluation of different brands of levofloxacin tablets (250mg) available in local market of Karachi (Pakistan), International Journal of Current Pharmaceutical Research, Vol 3, issue1, 1522.
[3]	Osonwa Uduma E., Agbokeayodeji A., Amadi Rosemary C., Okorie, Ogbonna and Opurum Christian C Bioequivalence studies on some selected brands of ciprofloxacin hydrochloride tablets in the Nigerian market with ciproflox as innovator brand, Journal of applied pharmaceutical science, 01 (06); 2011: 80-84.
[4]	Sajib Chakra B, & Zakaria A, Study of antimicrobial activity of ayurvedic and Unani medicine and their comparative analysis with commercial antibiotics, International journal of research in applied, natural and social sciences, Vol. 1, issue 3, Aug 2013, 63-74.
[5]	The United States Pharmacopoeia. United States Pharmacopoeia convention inc; Rockville, 2005.
[6]	Paulwilson, Sebastian E. Winter, Andreas J. Baumler. Clinical pathogenesis of typhoid fever. Department of medical microbiology and immunology, school of medicine, university of California, J infect developing countries 2008; 2(4): 260-266.
[7]	Hayat,A.S, Shaikh,N. Evaluation of Typhidot (igm) in early and rapid diagnosis of typhoid fever. Professional med journal, 2011. 18(2): 259-264.
[8]	Ghosh,S, Batabyal. P, Rajendran.K, PalitA. Typhoid fever in rural communities of West Bengal, India, Indian council of medical research, 2010: page 219-221.
[9]	Bryan C, Guntram A Grassl, Salmonella, the host and disease: A brief review, Immunology and cell biology, (2007) 85, 112-118.